Skip to content
Disclosery

Lion Point Capital, LP

Follow

13F filer, CIK 1643354, NEW YORK, NY

Lion Point Capital, LP reported $20,905,264 across 35 holdings for the quarter ended 2026-06-30, in a 13F-HR filed 2026-08-14. Its ten largest share positions make up 55.01% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001013594-26-000908

Period
2026-06-30
Reported value
$20.9M
Holdings
35
Top 10 weight
55.01%
New
1
Sold out
1

Largest buys vs the previous quarter

SecurityShares changeApprox. value
CUEnew+52,928$1.67M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
CUEexited-2,202,854-$506K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2026

Share positions as resolved from 13F-HR 0001013594-26-000908, largest first. % of portfolio is the value over $20,905,264, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
CUECUE BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 52,928 shares 52,928$1.67M7.99%newTimeline
PRAXPRAXIS PRECISION MEDICINES IQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 5,700 shares; 2025Q4: 4,450 shares; 2026Q1: 4,450 shares; 2026Q2: 4,450 shares 4,450$1.49M7.13%0Timeline
MLTXMOONLAKE IMMUNOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 67,500 shares; 2025Q4: 67,500 shares; 2026Q1: 67,500 shares; 2026Q2: 67,500 shares 67,500$1.31M6.29%0Timeline
FENCFENNEC PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 215,000 shares; 2024Q4: 195,700 shares; 2025Q1: 195,700 shares; 2025Q2: 195,700 shares; 2025Q3: 123,000 shares; 2025Q4: 112,434 shares; 2026Q1: 112,434 shares; 2026Q2: 112,434 shares 112,434$1.21M5.78%0Timeline
RPRXROYALTY PHARMA PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 21,400 shares; 2025Q4: 21,400 shares; 2026Q1: 21,400 shares; 2026Q2: 21,400 shares 21,400$1.2M5.74%0Timeline
CMPSCOMPASS PATHWAYS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 58,000 shares; 2025Q4: 58,000 shares; 2026Q1: 80,000 shares; 2026Q2: 80,000 shares 80,000$1.13M5.41%0Timeline
MISTMILESTONE PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 1,654,154 shares; 2024Q4: 1,025,806 shares; 2025Q1: 548,806 shares; 2025Q2: 548,806 shares; 2025Q3: 658,553 shares; 2025Q4: 755,000 shares; 2026Q1: 820,000 shares; 2026Q2: 820,000 shares 820,000$1.1M5.26%0Timeline
BNTCBENITEC BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 39,000 shares; 2024Q4: 62,000 shares; 2025Q1: 62,000 shares; 2025Q2: 62,000 shares; 2025Q3: 62,000 shares; 2025Q4: 62,000 shares; 2026Q1: 62,000 shares; 2026Q2: 62,000 shares 62,000$830K3.97%0Timeline
SNDXSYNDAX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 46,200 shares; 2024Q4: 55,000 shares; 2025Q1: 55,000 shares; 2025Q2: 55,000 shares; 2025Q3: 55,000 shares; 2025Q4: 36,000 shares; 2026Q1: 36,000 shares; 2026Q2: 36,000 shares 36,000$787K3.76%0Timeline
BHVNBIOHAVEN LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 35,400 shares; 2024Q4: 22,700 shares; 2025Q1: 22,700 shares; 2025Q2: 22,700 shares; 2025Q3: 22,700 shares; 2025Q4: 51,700 shares; 2026Q1: 51,700 shares; 2026Q2: 51,700 shares 51,700$769K3.68%0Timeline
GERNGERON CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 630,000 shares; 2024Q4: 500,000 shares; 2025Q1: 500,000 shares; 2025Q2: 500,000 shares; 2025Q3: 500,000 shares; 2025Q4: 578,000 shares; 2026Q1: 578,000 shares; 2026Q2: 578,000 shares 578,000$740K3.54%0Timeline
QUREUNIQURE NVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 14,700 shares; 2026Q1: 14,700 shares; 2026Q2: 14,700 shares 14,700$677K3.24%0Timeline
ARDXARDELYX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 370,000 shares; 2024Q4: 335,400 shares; 2025Q1: 335,400 shares; 2025Q2: 335,400 shares; 2025Q3: 162,750 shares; 2025Q4: 128,650 shares; 2026Q1: 128,650 shares; 2026Q2: 128,650 shares 128,650$656K3.14%0Timeline
LNTHLANTHEUS HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 5,500 shares; 2026Q1: 5,500 shares; 2026Q2: 5,500 shares 5,500$610K2.92%0Timeline
IRONDISC MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 7,700 shares; 2024Q4: 10,600 shares; 2025Q1: 10,600 shares; 2025Q2: 10,600 shares; 2025Q3: 10,600 shares; 2025Q4: 8,100 shares; 2026Q1: 8,100 shares; 2026Q2: 8,100 shares 8,100$592K2.83%0Timeline
SRPTSAREPTA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 28,500 shares; 2026Q1: 28,500 shares; 2026Q2: 28,500 shares 28,500$512K2.45%0Timeline
HUMAHUMACYTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 83,500 shares; 2025Q2: 83,500 shares; 2025Q3: 83,500 shares; 2025Q4: 500,000 shares; 2026Q1: 650,000 shares; 2026Q2: 650,000 shares 650,000$507K2.43%0Timeline
KURAKURA ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 46,000 shares; 2025Q4: 46,000 shares; 2026Q1: 46,000 shares; 2026Q2: 46,000 shares 46,000$505K2.41%0Timeline
VTRSVIATRIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 27,700 shares; 2026Q1: 27,700 shares; 2026Q2: 27,700 shares 27,700$440K2.1%0Timeline
DYNDYNE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 18,000 shares; 2026Q1: 18,000 shares; 2026Q2: 18,000 shares 18,000$400K1.91%0Timeline
BBIOBRIDGEBIO PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 49,000 shares; 2024Q4: 40,300 shares; 2025Q1: 26,000 shares; 2025Q2: 26,000 shares; 2025Q3: 13,300 shares; 2025Q4: 5,000 shares; 2026Q1: 5,000 shares; 2026Q2: 5,000 shares 5,000$372K1.78%0Timeline
EWTXEDGEWISE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 9,100 shares; 2026Q1: 9,100 shares; 2026Q2: 9,100 shares 9,100$370K1.77%0Timeline
PCRXPACIRA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 13,500 shares; 2026Q1: 13,500 shares; 2026Q2: 13,500 shares 13,500$342K1.64%0Timeline
RGNXREGENXBIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 57,750 shares; 2024Q4: 57,750 shares; 2025Q1: 57,750 shares; 2025Q2: 57,750 shares; 2025Q3: 57,750 shares; 2025Q4: 26,600 shares; 2026Q1: 26,600 shares; 2026Q2: 26,600 shares 26,600$319K1.52%0Timeline
RCKTROCKET PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 86,000 shares; 2025Q4: 86,000 shares; 2026Q1: 86,000 shares; 2026Q2: 86,000 shares 86,000$294K1.41%0Timeline
JANXJANUX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 19,000 shares; 2026Q1: 19,000 shares; 2026Q2: 19,000 shares 19,000$292K1.4%0Timeline
MLYSMINERALYS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 79,000 shares; 2024Q4: 79,000 shares; 2025Q1: 79,000 shares; 2025Q2: 79,000 shares; 2025Q3: 39,000 shares; 2025Q4: 10,500 shares; 2026Q1: 10,500 shares; 2026Q2: 10,500 shares 10,500$283K1.36%0Timeline
GHRSGH RESEARCH PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 10,200 shares; 2026Q1: 10,200 shares; 2026Q2: 10,200 shares 10,200$274K1.31%0Timeline
MCRBSERES THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 17,038 shares; 2025Q3: 27,138 shares; 2025Q4: 31,570 shares; 2026Q1: 31,570 shares; 2026Q2: 31,570 shares 31,570$249K1.19%0Timeline
AZTAAZENTA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 9,700 shares; 2026Q1: 9,700 shares; 2026Q2: 9,700 shares 9,700$248K1.18%0Timeline
JSPRJASPER THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 32,000 shares; 2024Q4: 32,000 shares; 2025Q1: 146,500 shares; 2025Q2: 146,500 shares; 2025Q3: 398,558 shares; 2025Q4: 465,000 shares; 2026Q1: 465,000 shares; 2026Q2: 465,000 shares 465,000$196K0.94%0Timeline
INVAINNOVIVA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 8,200 shares; 2026Q1: 8,200 shares; 2026Q2: 8,200 shares 8,200$186K0.89%0Timeline
IPHAINNATE PHARMA S AQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 81,151 shares; 2026Q1: 81,151 shares; 2026Q2: 81,151 shares 81,151$149K0.71%0Timeline
ARQTARCUTIS BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 35,100 shares; 2024Q4: 46,300 shares; 2025Q1: 46,300 shares; 2025Q2: 46,300 shares; 2025Q3: 35,300 shares; 2025Q4: 5,250 shares; 2026Q1: 5,250 shares; 2026Q2: 5,250 shares 5,250$138K0.66%0Timeline
SPRBSPRUCE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,000 shares; 2025Q4: 1,000 shares; 2026Q1: 1,000 shares; 2026Q2: 1,000 shares 1,000$54K0.26%0Timeline

Sold out in Q2 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
CUECUE BIOPHARMA INC2,202,854$506Kshares

How Q2 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001013594-26-000908 base2026-08-14acceptance time not in the bulk data set

Filings

Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.

FilingSubjectFiledAcceptedIngested
13F-HR 0001013594-26-000908 Quarter ended 2026-06-302026-08-14acceptance time not in the bulk data set
13F-HR 0001013594-26-000605 Quarter ended 2026-03-312026-05-15acceptance time not in the bulk data set
13F-HR 0001013594-26-000252 Quarter ended 2025-12-312026-02-17acceptance time not in the bulk data set
13F-HR 0001013594-25-001425 Quarter ended 2025-09-302025-11-14acceptance time not in the bulk data set
13F-HR 0001013594-25-001032 Quarter ended 2025-06-302025-08-14acceptance time not in the bulk data set
13F-HR 0001013594-25-000673 Quarter ended 2025-03-312025-05-15acceptance time not in the bulk data set
13F-HR 0001013594-25-000268 Quarter ended 2024-12-312025-02-14acceptance time not in the bulk data set
13F-HR 0001013594-24-000964 Quarter ended 2024-09-302024-11-14acceptance time not in the bulk data set
13F-HR 0001013594-24-000659 Quarter ended 2024-06-302024-08-14acceptance time not in the bulk data set
13F-HR 0001013594-24-000479 Quarter ended 2024-03-312024-05-15acceptance time not in the bulk data set
13F-HR 0001013594-24-000191 Quarter ended 2023-12-312024-02-14acceptance time not in the bulk data set
13F-HR 0001013594-23-000924 Quarter ended 2023-09-302023-11-14acceptance time not in the bulk data set
13F-HR 0001013594-23-000689 Quarter ended 2023-06-302023-08-14acceptance time not in the bulk data set
13F-HR 0001013594-23-000487 Quarter ended 2023-03-312023-05-15acceptance time not in the bulk data set
13F-HR 0001013594-23-000240 Quarter ended 2022-12-312023-02-14acceptance time not in the bulk data set
13F-HR 0001567619-22-019969 Quarter ended 2022-09-302022-11-14acceptance time not in the bulk data set
13F-HR 0001567619-22-016177 Quarter ended 2022-06-302022-08-15acceptance time not in the bulk data set
13F-HR 0001567619-22-010893 Quarter ended 2022-03-312022-05-16acceptance time not in the bulk data set
13F-HR 0001567619-22-004292 Quarter ended 2021-12-312022-02-14acceptance time not in the bulk data set
13F-HR 0001567619-21-020366 Quarter ended 2021-09-302021-11-15acceptance time not in the bulk data set
13F-HR 0001567619-21-015804 Quarter ended 2021-06-302021-08-16acceptance time not in the bulk data set
13F-HR/A 0001567619-21-010662 Quarter ended 2021-03-312021-05-19acceptance time not in the bulk data set
13F-HR 0001567619-21-010454 Quarter ended 2021-03-312021-05-17acceptance time not in the bulk data set
13F-HR 0001567619-21-003961 Quarter ended 2020-12-312021-02-16acceptance time not in the bulk data set
13F-HR 0001567619-20-019893 Quarter ended 2020-09-302020-11-16acceptance time not in the bulk data set
13F-HR 0001567619-20-015401 Quarter ended 2020-06-302020-08-14acceptance time not in the bulk data set
13F-HR 0001567619-20-010453 Quarter ended 2020-03-312020-05-15acceptance time not in the bulk data set
13F-HR 0001567619-20-003918 Quarter ended 2019-12-312020-02-14acceptance time not in the bulk data set
13F-HR 0001567619-19-021332 Quarter ended 2019-09-302019-11-14acceptance time not in the bulk data set
13F-HR 0001567619-19-016945 Quarter ended 2019-06-302019-08-14acceptance time not in the bulk data set
13F-HR 0001567619-19-011210 Quarter ended 2019-03-312019-05-15acceptance time not in the bulk data set
13F-HR 0001567619-19-004319 Quarter ended 2018-12-312019-02-14acceptance time not in the bulk data set
13F-HR 0001567619-18-006102 Quarter ended 2018-09-302018-11-14acceptance time not in the bulk data set
13F-HR 0001567619-18-001047 Quarter ended 2018-06-302018-08-14acceptance time not in the bulk data set
13F-HR 0001140361-18-023933 Quarter ended 2018-03-312018-05-15acceptance time not in the bulk data set
13F-HR 0001140361-18-007824 Quarter ended 2017-12-312018-02-14acceptance time not in the bulk data set
13F-HR 0001140361-17-042719 Quarter ended 2017-09-302017-11-14acceptance time not in the bulk data set
13F-HR 0001140361-17-031869 Quarter ended 2017-06-302017-08-14acceptance time not in the bulk data set
13F-HR 0001140361-17-020629 Quarter ended 2017-03-312017-05-15acceptance time not in the bulk data set
13F-HR 0001140361-17-006635 Quarter ended 2016-12-312017-02-14acceptance time not in the bulk data set
13F-HR 0001140361-16-086326 Quarter ended 2016-09-302016-11-14acceptance time not in the bulk data set
13F-HR 0001140361-16-076466 Quarter ended 2016-06-302016-08-15acceptance time not in the bulk data set
13F-HR 0001140361-16-065555 Quarter ended 2016-03-312016-05-16acceptance time not in the bulk data set
13F-HR 0001140361-16-053113 Quarter ended 2015-12-312016-02-16acceptance time not in the bulk data set